Search the Newsreel

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

Sionna Therapeutics announced that its experimental cystic fibrosis pill, SION-719, failed to show any additional benefit when used as an add-on therapy to Vertex Pharmaceuticals’ Trikafta in a Phase 2 trial. The company will discontinue the drug's development as an add-on and plans to …

Vertex Pharmaceuticals (VRTX) Eleva Su Guía Y Vuelve A Poner La Valoración En Foco

Vertex Pharmaceuticals (VRTX) On Guidance Upgrade And Pipeline Growth Narrative

Vertex Pharmaceuticals (VRTX) recently updated its full-year revenue guidance after strong Q2 2026 results and announced a new collaboration with AbCellera Biologics for autoimmune diseases. Despite a strong stock performance and a fresh bump to guidance, the company is considered undervalued with a fair …

Vertex Pharmaceuticals Incorpor (VRTX) Stock forecasts

Vertex Pharmaceuticals (VRTX) is a global biotechnology company focusing on small-molecule drugs, particularly for cystic fibrosis. Their earnings are supported by strong cystic fibrosis sales, aiding diversification efforts. The company's key drugs include Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek, which are market leaders in …

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 4.9% in the second quarter, selling 2,724 shares but still holding 53,380 shares valued at $26.5 million. Despite this sale, institutional investors own 90.96% of VRTX, and analysts generally maintain a …

Assenagon Asset Management S.A. Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Assenagon Asset Management S.A. significantly increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 41.4% in the second quarter, now owning 759,564 shares valued at $377.3 million. This comes as institutional investors collectively hold 90.96% of the company's stock, and analysts maintain a "Moderate Buy" …

Vertex (VRTX) Stock Looks Reasonably Priced As Its 155% Run Continues

Vertex Pharmaceuticals (VRTX) has seen a 155.4% return over five years, with its stock currently appearing reasonably priced. A Discounted Cash Flow (DCF) analysis suggests a 12.5% undervaluation, while its P/E ratio of 28.6x is close to the estimated fair multiple, indicating it's broadly …

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 9.9% in the second quarter, bringing its total holdings to 54,094 shares valued at $26.9 million. This acquisition is part of a larger trend of institutional investment, with such entities collectively owning 90.96% of …

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Vertex Pharmaceuticals Inc. (VRTX) saw its stock rise by 2.49% to $496.07 on a positive trading day, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average. Despite this gain, the stock remains 7.05% below its 52-week high.

How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors

Agios Pharmaceuticals reported a significant revenue increase in Q2 2026, reaching US$44.75 million, up from US$12.46 million a year prior, while net losses slightly narrowed. This growth is driven by the traction of recent approvals and launches, with the FDA's Priority Review of PYRUKYND …

Crinetics Pharmaceuticals (CRNX) Stock Looks Rich On Book Value But Reasonable On Deal Value

Crinetics Pharmaceuticals (CRNX) has experienced a significant stock price increase of 403.6% over three years, making its current valuation appear high on market multiples. While the agreed acquisition by Vertex Pharmaceuticals for US$10.0 billion helps justify the current price, the stock's Price-to-Book ratio of …

Vertex (VRTX) Stock Highlights Margin Strength As Launch Costs Climb

Vortex Energy Receives Final Technical Study Results for the Robinsons River Salt Project

VORTEX ENERGY CORP Study confirms western salt structure, identifies an eastern exploration target and establishes a staged technical pathway for further evaluation VANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") …

Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)

Vertex Pharmaceuticals reported strong financial results for Q2 2026, with total revenues increasing to $3.3 billion, driven by robust performance of its CF therapies and growth in other disease areas. The company is advancing a diversified pipeline, including new approvals for cystic fibrosis treatments, …

Acute pain drug Journavx helps drive Vertex growth in second quarter

Vertex Pharmaceuticals reported a 12% increase in second-quarter revenue, reaching $3.33 billion, largely driven by the strong performance of its non-opioid acute pain drug Journavx, which generated $50 million in revenue. The company raised its full-year 2026 revenue forecast to $13.1 billion to $13.2 …

Vertex Pharmaceuticals (VRTX) Stock Sostiene Márgenes Mientras Acelera La Diversificación

Vertex Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $563.21, Implies 20% Upside

Vertex Pharmaceuticals Incorporated (VRTX) has seen its average 12-month price target raised to $563.21 by 24 analysts, up from $560.25, with forecasts ranging from $350 to $653. This updated target suggests a potential upside of approximately 20% from its August 3 closing price. The …

Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD

Crinetics Pharmaceuticals' stock has reached an all-time high of $84.01, driven by a 187.21% increase over the past year and a market capitalization of $8.85 billion. This surge in value comes as Vertex Pharmaceuticals announced an agreement to acquire Crinetics for approximately $10 billion, …

Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says

Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Vertex Pharmaceuticals Inc. stock rises Tuesday, still underperforms market

Shares of Vertex Pharmaceuticals Inc. rose 1.70% on Tuesday, closing at $478.71. Despite this gain, the stock underperformed the broader market, as both the S&P 500 Index and the Dow Jones Industrial Average saw larger increases of 1.79% and 1.71%, respectively. The rise did, …

Vertex’s biggest overhang: a rival 50 times smaller

Vertex Pharmaceuticals reported strong Q2 earnings, exceeding Wall Street expectations and raising its annual guidance, primarily due to its successful cystic fibrosis drugs. However, a much smaller rival, Sionna Therapeutics, poses a potential threat with upcoming data from a mid-stage study of its cystic …

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals Incorporated VRTX raised its 2026 revenue outlook as cystic fibrosis growth and contributions from newer products accelerated. Management framed 2026 as an execution year, with commercial scaling, a near-term renal launch and the pending Crinetics acquisition shaping diversification. VRTX Raises Outlook as …

TD Cowen raises Vertex stock price target on solid Q2 results

TD Cowen has raised its price target for Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) to $550 from $525, maintaining a Buy rating, following strong second-quarter results and increased guidance. The company exceeded consensus estimates for cystic fibrosis revenue and non-GAAP earnings per share. Vertex also raised …

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

Vertex Pharmaceuticals reported a strong Q2 performance and subsequently raised its outlook, which RBC Capital Markets highlighted as an indicator of the company's fundamental business strength. The article suggests that these positive results are driving confidence in Vertex's core operations.

Vertex Pharmaceuticals’ Q2 Earnings Call Confirmed an $8.8 Billion Bet. Here’s What That Means for the Stock

Canaccord eleva el precio objetivo de Vertex a 442 dólares por superar los ingresos previstos

Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason

Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year. Continue Reading

Vertex unfazed by competitive IgAN space as FDA verdict looms

Vertex Pharmaceuticals' CEO, Reshma Kewalramani, expressed confidence in their upcoming IgA nephropathy (IgAN) drug, povetacicept, despite strong competition. She highlighted positive two-year follow-up data for Otsuka Pharmaceuticals' rival drug, Voyxact, as a good sign for the IgAN space. Kewalramani also emphasized povetacicept's strong proteinuria …

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ...

This article first appeared on GuruFocus. Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year. CF Revenue: Global CF revenue grew 11% year-over-year in Q2 2026. CASGEVY Revenue: $76 million in Q2 2026, up over 150% year-over-year. JOURNAVX Revenue: $50 million in Q2 …

Vertex Reports Second Quarter 2026 Financial Results

Vertex Pharmaceuticals reported strong second-quarter 2026 financial results, with total revenue increasing 12% to $3.33 billion. The company raised its full-year revenue guidance to $13.1 billion to $13.2 billion, driven by robust performance in cystic fibrosis therapies and growth in other disease areas like …

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex raises 2026 revenue guidance as CEO touts benefits of $10 billion Crinetics deal

Vertex Pharmaceuticals has raised its 2026 revenue guidance, with CEO Reshma Kewalramani highlighting the potential of the two main assets acquired from Crinetics Pharmaceuticals. These assets are projected to generate over $5 billion in combined annual revenue. The revised outlook follows Vertex's $10 billion …

Vertex Pharmaceuticals ups FY26 revenue view to $13.1B-$13.2B, consensus $13.05B

Vertex Pharmaceuticals has increased its full-year 2026 total revenue guidance to $13.1 billion-$13.2 billion, up from its previous range of $12.95 billion-$13.1 billion, surpassing the consensus of $13.05 billion. This revised outlook includes continued growth from cystic fibrosis products and at least $500 million …

Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Vertex Pharmaceuticals (VRTX) reported revenue of $3.33 billion, up 12.5% over the same period last year. EPS came in at $4.73, compared to $4.52 in the year-ago quarter. The reported revenue represents a surprise of +3.32% over the …

Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates

Vertex Pharmaceuticals (VRTX) reported Q2 earnings of $4.73 per share, missing the Zacks Consensus Estimate of $4.79, but revenue of $3.33 billion surpassed expectations. The company's stock has underperformed the S&P 500 year-to-date, and its current Zacks Rank is #3 (Hold), indicating it's expected …

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company's full-year revenue guidance of $13.15 billion at the …